Publication: 2456

The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance)
      QxMD      Google Scholar   
Citation:
Lancet Haematol vol 3 (7) e309-e316
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
5
Parents:
2270   2316   2387  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
R01 CA127433, U10 CA180821, U10 CA180790, U10 CA180882, P50 CA097274, U10 CA180867, U10 CA025224  
Corr. Author:
 
Authors:
                     
Networks:
LAPS-MN026   
Study
NCCTG-N1085
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1
Keywords:
Everolimus, mTORC1, DLBCL